In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months

Jennifer Clark, Victor Montori

Research output: Contribution to journalComment/debatepeer-review

Abstract

SOURCE CITATION: Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507-19. 32187462.

Original languageEnglish (US)
Pages (from-to)JC18
JournalAnnals of internal medicine
Volume173
Issue number4
DOIs
StatePublished - Aug 18 2020

ASJC Scopus subject areas

  • Internal Medicine

Fingerprint

Dive into the research topics of 'In patients with ASCVD and elevated LDL-C with maximal statin therapy, inclisiran reduced LDL-C levels at 18 months'. Together they form a unique fingerprint.

Cite this